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Abstract 
 
Background: To determine the efficacy and side 
effects of oral misoprostol versus syntometrine for 
prevention of primary postpartum hemorrhage. 
 Methods: Interventional study; Eighty patients were 
divided into two equal groups.  Misoprostol 600 
microgram single dose was given orally immediately after 
cord clamping to Group A. Syntometrine (consists of 10 IU 
oxytocin + 0.5mg ergometrine) was given intravenous to 
Group B.  Patients were kept under observation for 6 
hours. Pulse, blood pressure, temperature any need for 
other uterotonic drugs, estimated blood loss (<500ml or 
>500ml) haemoglobin percentage 6hours before and after 
delivery, need for blood transfusion, side effects, time and 
mode of delivery were noted. 
Results: Differences in blood pressure and transfusion  
were statistically insignificant between two groups. 
Shivering and pyrexia was more common in Group A , and 
nausea, vomiting and hypertension in Group B 
Conclusion: Like syntometrine, misoprostol can be 
used prophylactically orally during third stage of labour to 
reduce the incidence of Primary postpartum hemorrhage. 
Keywords: Primary postpartum hemorrhage, uterine 
atony, Prostaglandins, oxytocin, ergot alkaloids. 
 
Introduction 
 
Primary postpartum hemorrhage remains a 
significant cause of maternal mortality and morbidity, 
responsible for 30% of maternal deaths .Uterine atony 
or failure of the uterus to contract following delivery is 
the most common cause of primary postpartum 
hemorrhage. 1-3 
Multiple uterotonic agents have been used for 
prevention of primary postpartum hemorrhage. 
Conventional oxytocic agents include oxytocin, 
syntometrine and prostaglandins. Oxytocin the ergot 
alkaloid and syntometrine are equally effective in 
reducing risk of postpartum hemorrhage and is 
associated with specific maternal side effects, like 
nausea, vomiting and headache. 4-5 
As compared to Syntometrine, Misoprostol 
has many advantages, as it can be given via  variety  of 
routes (oral,rectal,sublingual,vaginal); it does not need 
refrigeration; has a long shelf life; low cost and is 
stable at high temperature6. It is very effective for 
control of primary PPH, when given orally or rectally 
as 600 microgram .7,8 Specific side effects of 
misoprostol are dose related and include, shivering, 
transient pyrexia, nausea and vomiting9.  
In many developing country settings where 
primary and referred level health facilities often do not 
have the necessary health personnel, supplies or 
equipment to administer conventional uterotonic 
drugs routinely, misoprostol represents a reasonable 
alternative agent for management of third stage of 
labour. In addition oxytocin, requires refrigeration, 
special storage, use of needles and syringes.  
 
Patients and Methods 
 
This interventional study was  carried  out 
over a period of six months from 17th April 2009 to 17th 
October 2009 in the department of Obstetrics and 
Gynecology at District Headquarter Teaching Hospital 
Rawalpindi. Using formula n=Z2 Pq/E2 Sample size 
was 80 women divided into two groups. 40  patients in 
Group A were given Misoprostol and 40 patients in 
Group B were given Syntometrine.  
Women of all age groups, booked or non 
booked with singleton, term pregnancy with cephalic 
presentation undergoing spontaneous vaginal delivery 
were included in the study. Women with previous 
Caesarean Section, Grand Multiparty (>Parity 4), 
anaemia, systolic blood pressure > 140mm of mercury 
and diastolic >90mm of mercury, intrauterine fetal 
demise., multiple pregnancies, medical conditions 
including diabetes, cardiac ailments, seizures and 
bronchial asthma, obstetric complications i.e breech, 
pre-eclampsia and chorioamnionitis, and with history 
of complications (ante / postpartum hemorrhage, 
retained placenta / acute inversion of uterus) during 
previous pregnancy were excluded from study. 
Single blind technique was used to avoid 
patient bias. Partogram was maintained and labour 
monitored routinely.  
Journal of Rawalpindi Medical College (JRMC); 2010;14(1):43-45 
 44 
Misoprostol 600µg single dose orally 
immediately after cord clamping was given to Group 
A and Syntometrine (which consists of 10 IU oxytocin 
+ 0.5mg ergometrine) was given to Group B. 
Patient was observed for  pulse, blood 
pressure, temperature, any need for other uterotonic 
drugs, estimated visual blood loss (< 500ml or > 
500ml) hemoglobin percentage before and after 
delivery need for blood transfusion. Side effects, time 
and mode of delivery were also noted.  
Paired sample t-test was used to compare 
hemoglobin before and after delivery and independent 
sample t-test was applied to compare blood loss in 
Misoprostol and Syntometrine groups. P value less 
than 0.05 was considered as significant.    
 
Results 
 There were 15% primigravidas and 85% 
multigravida in Group A, while 10% and 90% 
respectively in Group B. In Group A 40% required 
Augmentation of labour as compared to 42.5% in 
Group B . In Group A 15% and in Group B 20% 
patients, required induction of labour (Table 1).  
 
Table 1:  Misoprostol Vs Syntometrine: 
Augmentation and induction of labour 
  Misoprostol 
Patients (%) 
Syntometrine  
Patients (%) 
Augmentation 
of labour 
 
Yes 16(40% 17(42.5% 
No 24(60%) 23(57.5%) 
Induction  
 of Labour 
Yes 8(20%) 6(15%) 
No 32(80%) 34(85%) 
 
 There was no statistically significant 
difference regarding blood loss and blood transfusions 
between Group A and B(Table 2 ; fig 1) 
There was statistically insignificant value 
difference in mean duration of stages of labour in both 
groups (Table 3).  
In Group A, 5% patients experienced nausea 
and 20% experienced vomiting   while it was 20% and 
40% in Group B respectively. These side effects were 
statistically non-significant in both groups.  In Group 
A, 45% patients experienced shivering and 30% had 
pyrexia which were statistically significant (p<0.05) 
while no cases of shivering and pyrexia were noted  in 
group B (Table 4). 
In Group B 13.3% patients experienced 
headache but it was statistically non significant. 
Hypertension was statistically significant in Group B 
while no cases were seen in Group A (p- value 0.040) 
Table 2: Misoprostol Vs Syntometrine: 
Requirement of Blood Transfusion  
 Misoprostol 
No. (%) 
Syntometrine 
No. (%) 
Yes 2(5) 1(2.5% 
No 38(95%) 39(97.5%) 
 
Table-3: Descriptive statistics for different 
stages  stage of labour 
 Group  Mini-
mum 
Maxi-
mum 
Mean Standard 
deviation 
1st A Misoprostol 4 9 6.5 2.5 
B Syntometrine 3 9 6 3 
2nd A Misoprostol 5 30 17.5 12.5 
B Syntometrine 10 35 22.5 12.5 
 
Table4: Comparison of side effects in both 
drug groups 
Side Effects Misoprostol No. (%) 
Syntometrine 
      No. (%) p-Value 
Nausea 1(5) 3(20%) 0.305 
Vomiting 4(20%) 6(40%) 0.499 
Shivering 9(45%)0 0 0.001* 
Pyrexia 6(30%) 0 0.011* 
Headache 0 2(13.3%) 0.152 
Hypertensio
n 0 4(26.6%) 0.04 
*Significant at 5% Level of Significance  
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Fig 1: Blood loss for groups:  
 
Discussion 
 
An ideal agent used to prevent PPH as 
prophylaxis should be effective, convenient, safe and 
inexpensive. It should prevent PPH without significant 
side effects. 
Misoprostol has powerful uterotonic effects 
and in this way prevents PPH like other uterotonic 
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agents. In contrast to oxytocin they are effective, safe 
and inexpensive. Misoprostol can be given via variety 
of routes (oral, rectal, sublingual, and vaginal): It does 
not need refrigeration, has a long shelf life and stable 
at high temperature. 10 Oral Misoprostol is associated 
with a significant reduction in the rate of acute severe 
postpartum hemorrhage. The drug’s low cost, ease of 
administration, stability and positive safety profile 
make it a good option in resource-poor setting.10. 
Effective use of oxytocin requires 
refrigeration, sterile equipment for safe injection, and 
trained medical providers for administration. Given 
these constraints, misoprostol has been investigated as 
a potential alternative therapy for PPH prevention. 
Regarding side effects of Syntometrine a study 
conducted and published in 2007 concluded that ergot 
alkaloids in the third stage of labour significantly 
decreased mean blood loss and were associated with 
increased risk of vomiting, elevation of blood pressure 
and pain after birth requiring analgesia, particularly 
with the intravenous route of administration . 11 
Randomized controlled trials,   comparing 
Misoprostol versus conventional injectable  uterotonic 
in prevention of PPH, concluded that as a stable, orally 
active and cheap uterotonic, Misoprostol  would 
appear ideally suited to the prevention of postpartum 
hemorrhage in the developing world. Misoprostol is 
therefore indicated for prevention of PPH in settings 
where injectable conventional uterotonics are not 
available15. 
Although effective methods for prevention 
and treatment of PPH exist such as oxytocin and ergot 
alkaloids, most are not feasible in resource poor 
settings where many births occur at home. Oral 
misoprostol is a potential alternative which could 
prevent postpartum hemorrhage in a community 
home birth setting. 
In conclusion,Misoprostol is effective and cheaper 
alternative to Syntometrine in rural low resource 
settings, where the majority of deliveries take place at 
home without a skilled birth attendant present, and 
women face great risk of serious complication or even 
death from PPH due to limited access to emergency 
maternal health care services. The drug’s low cost, 
ease of administration, stability at room temperature 
and a positive safety profile make it a good option in 
resource-poor settings.  
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